Crinetics Pharmaceuticals CRNX Business Segments — Other Research and Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — other research and development expense?
- Crinetics Pharmaceuticals (CRNX) reported business segments — other research and development expense of $8.3M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — other research and development expense changed year-over-year?
- Crinetics Pharmaceuticals's business segments — other research and development expense increased by 23.2% year-over-year, from $6.74M to $8.3M.
- What does business segments — other research and development expense mean?
- This metric captures miscellaneous research and development costs that are not directly attributable to specific clinical programs or personnel. It may include overhead, facility costs, or general laboratory expenses necessary to support the broader R&D infrastructure. Tracking this helps identify the underlying operational costs of maintaining a research organization.